贝舒地尔200mg的2024年在哪里能买到?

Besudil 200mg has been launched in China on August 1, 2023. The ways to purchase Besudil in 2024 include the following:

1. Hospital pharmacy:

Patients can purchase Besudil directly at the hospital pharmacy after the doctor issues a prescription.

2. Online pharmacies:

With the development of the Internet, some regular online pharmacies may also provide Besudil sales services. Patients can choose a reputable online pharmacy to purchase, but be sure to ensure the legality of the pharmacy and the authenticity of the medicines.

3. Official channels of pharmaceutical companies:

The manufacturer of Besudil may provide official purchase channels, and patients can purchase directly through the official website or customer service.

4. Overseas medical service institutions:

Domestic professional overseas medical service institutions can help patients obtain drugs. They may have cooperation with pharmacies at home and abroad and can help patients obtain medicines, which are guaranteed to be genuine and delivered to their homes, but patients need to find professional, formal and qualified medical service institutions online.

5. Drug agents:

Drug agents are the bridge connecting pharmaceutical companies and medical institutions. They may be another way to purchase Besudil. Patients can get detailed information about their medications and learn about the purchasing process and prices by contacting these agents.

About Besudil

Besudil is a prescription medicine used to treat adults and children 12 years and older who have chronic graft-versus-host disease (chronic GVHD) after you have received at least 2 prior treatments (systemic therapy) and have not received treatment. is an investigational, oral, selective Rho-associated coiled-coil protein kinase 2 (ROCK2) inhibitor that reduces type 17 and follicular T helper cells by down-regulating STAT3 and enhances regulatory T cells by up-regulating STAT5.

Instructions for taking Besudil

If the patient has any of the following conditions, he or she must inform the doctor:

1. Has kidney or liver problems.

2. Are pregnant or planning to become pregnant.

3. Currently breastfeeding or planning to breastfeed.

4. Tell the doctor about all the medications the patient takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

5. Besudil treatment has not been studied in patients with previous severe renal impairment. Consider the risks and potential benefits before initiating treatment with besudil in patients with preexisting severe renal insufficiency.

Therapeutic efficacy of besudil

KD025-213 (NCT03640481) was a randomized, open-label, multicenter dose-ranging trial that evaluated the efficacy of besudil 200 mg orally once daily in 65 patients with chronic GVHD.

The primary efficacy outcome measure was overall response rate (ORR) on Day 1 of Cycle 7, where ORR included complete response (CR) or partial response (PR), according to the NIH Chronic Graft Clinical Trials Consensus Development Program 2014 criteria for versus host disease. The ORR was 75%; 6% of patients achieved CR and 69% achieved PR. Median time to first response was 1.8 months.

The median duration of response calculated from first response to progression, death, or chronic GVHD with new systemic therapies is 1.9 months. Among patients who achieved remission, 62% were free of death or initiation of new systemic therapy for at least 12 months after remission.

Summary

Besudil tablets are ROCK2 inhibitors approved by the US FDA for the treatment of cGVHD. The drug has previously been granted breakthrough therapy and priority review status by the FDA. It is recommended that patients take the drug under the guidance of a doctor and treat it symptomatically.

Recommended hot articles: